Last reviewed 2026-04-20 · How we verify

Administration of 131 iodine

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Fatigue
• Hypertension
• Nausea
• Diarrhoea
• Proteinuria
• Weight decreased
• Arthralgia
• Decreased appetite
• Headache
• Vomiting
• 33300-Febrile neutropenia
• Back pain

Key clinical trials

• Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom (PHASE2)
• Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas (PHASE1)
• S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma (PHASE3)
• Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma (PHASE2)
• The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer (PHASE2)
• 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (PHASE2)
• Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation (PHASE2)
• Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Administration of 131 iodine CI brief — competitive landscape report
• Administration of 131 iodine updates RSS · CI watch RSS
• Assistance Publique - Hôpitaux de Paris portfolio CI